心血管疾患の患者の医薬品ケアのためのリスク分層化ツール
Anna de Dios Lopez1, Esther Vicente Escrig2, Paloma Sempere Serrano3
1Farmacia Hospitalaria, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
まとめ
新しいツールは 心血管疾患の患者を 薬剤治療の必要性によって分類します 患者の改善のために 医療資源の最適化や 介入の調整に役立ちます
科学分野:
- 心臓病科
- 薬理学について
- 医療サービス研究
背景:
- 心血管疾患 (CVD) の管理には,パーソナライズされた医薬品のアプローチが必要です.
- 既存のリスク分層化ツールは,医薬品のケアニーズを完全に捉えることができないかもしれません.
研究 の 目的:
- 心臓病患者の薬剤治療のためのリスク分級ツールを開発し,検証する.
- 総合的で個別化された 医薬品の介入を可能にします
主な方法:
- 心血管リスクの専門医による共同開発
- カイザー・パーマナンテのピラミッドモデル
- 4つの次元で20の変数を特定し,重みを割り当て,3つの優先度レベルを確立しました.
主要な成果:
- このツールは,患者さんを優先度1 (≥23ポイント),優先度2 (17-22ポイント),および優先度3 (<16ポイント) に分類します.
- 臨床/医療利用と治療の要因は,全体のスコアに80%以上貢献しました.
- 患者の優先順位に基づいた 薬剤治療の介入を推奨する
結論:
- 開発されたツールは,集中的な薬剤治療を必要とする心血管疾患の患者を効果的に特定します.
- 医療能力とリソースの割り当ての調整を容易にする.
- より広範な適用性のために,代表的な集団でのさらなる検証が推奨されます.
関連する概念動画
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
3.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.2K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
174
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
119
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
119
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33